GI related disorders
Microbiome-related Gastrointestinal Disorders Emerging data from epidemiologic, microbiome, and physiology research provide evidence of a linkage between alterations in the intestinal microbiome and several chronic GI diseases.
The growing understanding that the intestinal microbiota plays a role in GI biochemical, immunological and physiological functions has led to the increased interest in targeting the intestinal microbiota for treatment of GI disorders. However, the currently used interventions including antibiotics, prebiotics, probiotics, and fecal microbiome transplant (FMT) have not shown consistent beneficial effects. Biomica is focusing on two microbiome driven GI disorders, inflammatory bowel diseases (IBD) and functional GI and motility disorders (e.g., irritable bowel syndrome).
Using our computational predictive biology capabilities we identified BMC333: rationally-designed microbial consortia with potential anti-inflammatory activity in IBD. In IBS we utilize proprietary data from several clinical trials conducted in the US to develop a novel microbiome based drug.
BMC333 is an optimized drug candidate derived from Biomica’s drug candidates BMC321 and BMC322.